How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

27,767 results for

Respiratory Medications in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update July 2018 In partnership withComparative Effectiveness Review Number 211 Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov and Patient (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact epc@ahrq.hhs.gov. Suggested citation: Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update. Comparative Effectiveness Review No. 211. (Prepared by the RTI International–University of North Carolina

2018 Effective Health Care Program (AHRQ)

2. Observational Study of Drug Naive Diabetes Receiving Insulin Therapy

: August 30, 2021 Resource links provided by the National Library of Medicine related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment Type 2 Diabetes drug naive Type 2 Diabetes received insulin therapy Drug: Insulin Continuous Subcutaneous Insulin Infusion normal control healthy volunteers as normal control Outcome Measures Go to Primary Outcome Measures : Circulating immunity cell profiles [ Time Frame: 7 days ] profiles of circulating immunity cells such as T cells (...) -steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs consists with other endocrine diseases pregnancy cancer use of antibiotics in 3 months chronic digestive inflammations magnetic resonance imaging contraindications Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its

2018 Clinical Trials

3. Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model

Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model Estimated Study Start Date : January 1, 2019 Estimated Primary Completion Date : July 1, 2020 Estimated Study Completion Date : July 1, 2020 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention (...) Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2018 Clinical Trials

4. A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-admin

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-admin A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual (...) the PK of the study drugs. Additionally, any GI surgery (e.g., partial gastrectomy, pyloroplasty) including cholecystectomy that may impact drug absorption. Any major surgery, as determined by the investigator, within 4 weeks of first IMP dosing. Donation of > 400 mL of blood within 8 weeks or donation of plasma (except at the Screening Visit) within 4 weeks of first IMP dosing. Blood transfusion within 4 weeks of first IMP dosing. Inability to tolerate oral medication. Inability to tolerate

2017 Clinical Trials

5. Herbal cannabis and pharmaceutical cannabinoid treatment following motor vehicle accidents: A state of the science review

of prescription drug therapy 1 1.2 ICBC prescription medication funding policy 2 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada 2 2.0 An overview of a graduated evidence-informed, ICBC funding model 3 2.1 Funding policy decisions within a graduated, evidence informed ICBC funding model 5 2.2 Pharmaceutical cannabinoid medications for regulatory approved indications (LEVEL 1) 6 2.3 Pharmaceutical cannabinoids for indications without regulatory approval (LEVEL 2) 6 (...) and a doctor’s prescription which, to some extent, it adjudicates as to the appropriateness of diagnosis and the type and volume of drugs prescribed. Decisions regarding funding of herbal cannabis and pharmaceutical cannabinoidss fit within this well established ICBC funding policy framework. 1.3 Herbal cannabis and pharmaceutical cannabinoids in clinical medical practice in Canada The application of scientific medical knowledge of herbal cannabis and pharmaceutical cannabinoid therapy to clinical medical

2020 Therapeutics Letter

6. Drug therapy during pregnancy: implications for dental practice. (Abstract)

Drug therapy during pregnancy: implications for dental practice. Pregnancy is accompanied by various physiological and physical changes, including those found in the cardiovascular, respiratory, gastrointestinal, renal and haematological systems. These alterations in the pregnant patient may potentially affect drug pharmacokinetics. Also, pharmacotherapy presents a unique matter due to the potential teratogenic effects of certain drugs. Although medications prescribed by dentists are generally (...) safe during pregnancy, some modifications may be needed. In this article we will discuss the changes in the physiology during pregnancy and its impact on drug therapy. Specific emphasis will be given to the drugs commonly given by dentists, namely, local anaesthetics, analgesics, antibiotics and sedatives.

2016 British Dental Journal

7. CRACKCast E178 – Co-Morbird Medical Emergencies During Pregnancy

CRACKCast E178 – Co-Morbird Medical Emergencies During Pregnancy CRACKCast E178 - Co-Morbird Medical Emergencies During Pregnancy - CanadiEM CRACKCast E178 – Co-Morbird Medical Emergencies During Pregnancy In by Chris Lipp May 17, 2018 This episode of CRACKCast covers Rosen’s Chapter 178, Co-Morbid Medical Emergencies during Pregnancy. This chapter covers many complicated issues that arise during the care of pregnant patients already suffering from concomitant medical illness, and how to manage (...) these conditions balancing risks to both mother and fetus. Shownotes – Key Concepts The physiologic demands of pregnancy may cause previously occult medical conditions to become apparent and known problems to deteriorate rapidly. The physiologic adjustments of pregnancy alter the normal ranges for certain laboratory values. The adjusted values need to be considered in the interpretation of results. The possibility of pregnancy should be considered in the differential diagnosis of certain conditions, including

2018 CandiEM

8. Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults

Disease Gynaecology Womens Sexual Health and Benign Breast Disease Haematology and Blood Products Health Promotion and Protection including Screening Immunology and Allergy Infectious Disease and Immunisation Mens Health and Sexual Health Mental Health Drug Abuse and Learning Difficulties Musculoskeletal Neurology and Neurosurgery Other Paediatrics and Neonatology Pregnancy and Childbirth Radiology Imaging and Nuclear Medicine Rehabilitation and Disability Renal Disease and Urology Respiratory Disease (...) Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults Cannabidiol in a pharmaceutical formulation (Epidiolex; GWP42003-P) for Lennox-Gastaut syndrome in children and adults | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed

2017 NIHR Innovation Observatory

9. Coronavirus (COVID-19) and Pregnancy: What Maternal-Fetal Medicine Subspecialists Need to Know

Coronavirus (COVID-19) and Pregnancy: What Maternal-Fetal Medicine Subspecialists Need to Know Coronavirus (COVID-19) and Pregnancy: What Maternal-Fetal Medicine Subspecialists Need to Know 4.11.20 (this is an update from draft posted on 3-17-2020) The Society for Maternal-Fetal Medicine (SMFM); Sarah Dotters-Katz, MD, MMHPE; and Brenna L. Hughes, MD, MSc On March 11, 2020, the World Health Organization declared the COVID-19 outbreak [caused by severe acute respiratory syndrome coronavirus 2 (...) - guidance.html). What is known about COVID-19 in pregnancy? Currently, there is limited information from published scientific reports about the susceptibility of pregnant women to COVID-19 and severity of infection. Available data are still limited to small case series. In general, pregnant women experience immunologic and physiologic changes that make them more susceptible to viral respiratory infections. The initial characterization of pregnant women as a high-risk group was based largely on this fact

2020 Society for Maternal-Fetal Medicine

10. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum

different drugs and the impact of exposure at multiple time points in pregnancy (Reis and Kallen, 2010). The evidence we have on efficacy for most medications spe- cifically in the perinatal period are also poor. Most RCTs of psy- chotropics exclude women who are pregnant or breastfeeding. In general, guidelines (e.g. (NICE, 2015a; SIGN, 2012)) have extrapolated efficacy findings from non-pregnant and non- breastfeeding individuals. This seems reasonable as there is little evidence to suggest (...) ), UKTIS published monographs (https://www.toxbase.org/) and consensus among the authors following iterative circulation of the guideline manuscript. Given the broad scope of the literature on the risks of all classes of psychotropic drugs in the perinatal period, the risk/ benefit ratios for pharmacological treatments across all psychiat- ric disorders (in pregnancy and, when this is not available, in non-pregnant women and men) and the impact of these disorders themselves on fetal and infant outcomes

2017 British Association for Psychopharmacology

11. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

in pregnancy. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period ABSTRACT: Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines (...) and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period. Although relatively less information currently exists for the use of calcium channel blockers for this clinical indication, the available evidence suggests that immediate release oral nifedipine also may be considered as a first-line therapy, particularly when intravenous access is not available. In the rare circumstance that intravenous

2017 American College of Obstetricians and Gynecologists

12. Medication use during pregnancy and lactation

trimester (recommendation) • Women with chronic disorders should discuss medication use with their doctor before becoming pregnant (pre-pregnancy counseling) (recommendation) • Serum concentrations of medication with a narrow therapeutic range should be monitored in pregnancy as pharmacokinetic changes may require dose adjustments (recommendation) • Most women who use medication may breastfeed, because the benefits of breast milk outweigh the disadvantages of drugs (recommendation) Literature search (...) of the uterus and thus increasing the risk of spontaneous abortion or preterm delivery (i.e. misoprostol) • altering blood flow to the placenta (i.e. ACE inhibitors) Some medicines should not be used close to delivery because they may affect the delivery or the newborn child (i.e. NSAIDs). For example, some newborns have respiratory problems if the woman has used benzodiazepines or opioids over time closely with birth (3). Pharmacokinetic conditions during pregnancy Serum concentrations of some medications

2015 Nordic Federation of Societies of Obstetrics and Gynecology

13. Respiratory Medications in Pregnancy

Medications in Pregnancy Respiratory Medications in Pregnancy Aka: Respiratory Medications in Pregnancy II. Background Pregnancy Categories will be replaced on medication bottles with specific warnings and precautions by 2020 in U.S. Although are no longer FDA designated, they are included here As of 2018, succinct guidance (to replace ABCDX) on specific drugs in pregnancy is lacking III. Class B: No risk in controlled animal studies Cromolyn (Intal) ( ) ( , ) ( ) - not in Briggs (1998) Nedocromil (Tilade (...) Respiratory Medications in Pregnancy Respiratory Medications in Pregnancy Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Respiratory

2018 FP Notebook

14. Upper Respiratory Medications in Pregnancy

Upper Respiratory Medications in Pregnancy Upper Respiratory Medications in Pregnancy Aka: Upper Respiratory Medications in Pregnancy , Cold Preparations in Pregnancy II. Background Pregnancy Categories will be replaced on medication bottles with specific warnings and precautions by 2020 in U.S. Although are no longer FDA designated, they are included here As of 2018, succinct guidance (to replace ABCDX) on specific drugs in pregnancy is lacking III. Class B: No risk in controlled animal studies (...) Iodides VI. References Briggs (1998) Drugs in Pregnancy and , 5th ed Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Upper Respiratory Medications in Pregnancy." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Related Topics in Obstetrics About FPnotebook.com is a rapid access, point-of-care medical reference for primary care and emergency clinicians

2018 FP Notebook

15. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

-for-gestational-age baby 46 1.17 Large-for-gestational-age baby 46 1.18 No antenatal care 47 1.19 Previous caesarean section 50 1.20 Labour after 42 weeks of pregnancy 52 T erms used in this guideline 52 Recommendations for research 54 1 Subarachnoid haemorrhage or arteriovenous malformation of the brain 54 2 Needle siting in pregnant women who are obese 54 Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121) © NICE 2019. All rights reserved. Subject (...) during pregnancy. NICE has published a guideline on diabetes in pregnancy. T o find out why the committee made the recommendations on information for women with existing medical conditions and how they might affect practice, see rationale and impact. 1.2 Planning for intrapartum care with women with existing medical conditions – involving a multidisciplinary team 1.2.1 A multidisciplinary team led by a named healthcare professional should involve a pregnant woman with a medical condition in preparing

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs

Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs (IMAT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02167425 Recruitment Status : Unknown Verified November 2015 by Pangaea Global AIDS Foundation. Recruitment status

2014 Clinical Trials

17. Update on COVID-19 epidemiology and impact on medical care in children: April 2020

) and underline the primary importance of meticulous environmental cleaning [ ] . Managing children and youth infected with symptomatic COVID-19 No treatment for COVID-19 is proven to be effective at the present time, and early reports from trials of hydroxychloroquine in adults have not demonstrated any beneficial effect on morbidity or mortality [ ] . Several Canadian universities, research centres, and medical organizations have recommended against using of off-label, investigational therapies (...) (PHAC) has suggested that wearing a non-medical mask can prevent spread of respiratory droplets from contaminating others or landing on surfaces. Both the PHAC and the American Academy of Pediatrics (AAP) have indicated that masks covering the nose and mouth can be used by adults and by children over 2 years of age in community settings, for short periods, when physical distancing measures cannot be taken [ ] [ ] . Remind patients that touching the mask is a risk factor for contamination of hands

2020 Canadian Paediatric Society

18. A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Men or non-pregnant women 18 to 65 years of age. Signed informed consent form that meets all criteria of current Food and Drug Administration (FDA) regulations. Females of childbearing potential must not be pregnant or lactating (as confirmed by a negative urine pregnancy test Ability to use inhalation aerosol correctly. Exclusion Criteria: Any clinically significant finding on physical exam in the opinion of the Investigator (...) Respiratory, LLC) in Subjects With Stable, Mild Asthma Condition or disease Intervention/treatment Phase Asthma Drug: Zero-dose Drug: 90 mcg of PROAIR® HFA Drug: 180 mcg of 90 mcg of PROAIR® HFA Drug: 90 mcg of albuterol sulfate inhalation aerosol Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 123 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Quadruple (Participant, Care Provider

2018 Clinical Trials

19. A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome

, psychiatric, or cardiovascular disease, or other condition which would jeopardize safety or impact validity of results (per investigator). Currently taking felbamate. Compromised respiratory function or severe respiratory insufficiency. Pregnant or lactating female.. In the opinion of the investigator, the patient is unsuitable in any other way to participate in this study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may (...) . Condition or disease Intervention/treatment Phase Prader-Willi Syndrome Drug: Cannabidiol Oral Solution Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 66 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients

2018 Clinical Trials

20. A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: Test (T) Fluticasone propionate 100 mcg and Salmeterol 50 mcg inhalation powder/Respirent Pharmaceuticals Drug: Fluticasone Propionate 100 mcg and Salmeterol 50 mcg inhalation Powder/Respirent Pharmaceuticals new generic product of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder twice daily inhalation throughout the study Active Comparator: Reference (...) inhaled, intranasal, or systemic corticosteroid therapy. History of hypersensitivity to lactose Medication(s) with the potential to affect the course of asthma or to interact with sympathomimetic amines, e.g.: β-blockers, oral decongestants, benzodiazepines, digitalis, phenothiazines, polycyclic antidepressants, monoamine oxidase inhibitors. Viral or bacterial, upper or lower respiratory tract infection or sinus or middle ear infection within 4 weeks prior to the screening visit or during the run

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>